Healthy Skepticism Library item: 6652

Warning: This library includes all items relevant to health product marketing that we are aware of regardless of quality. Often we do not agree with all or part of the contents.

Publication type: Journal Article

Lexchin J, Vitry A.
Re: the promotion of Arcalion (sulbutiamine) and Duxaril (almitrine/raubasine)
1996 Feb;

Abstract:

Servier has responded to the questions that MaLAM asked in its previous letter about the marketing of Arcalion (sulbutiamine) and Duxaril (almitrine/raubasine). MaLAM is still concerned that neither of the two drugs have proven efficacy for the listed indications and that the risk to benefit ratio for Duxaril is unfavourable.

Keywords:
*analysis/Philippines/developing countries/Servier/ Arcalion/ almitrine/ raubasine/ sulbutiamine/ Duxaril/neurologic drugs/safety & risk information/quality of information/Medical Lobby for Appropriate Marketing/MaLAM/ETHICAL ISSUES IN PROMOTION: COMPANY STANDARDS/EVALUATION OF PROMOTION: DRUG SAFETY/PROMOTION AND HEALTH NEEDS: PROMOTION IN DEVELOPING COUNTRIES/PROMOTION IN SPECIFIC THERAPEUTIC AREAS: NEUROLOGIC DISEASES